Document is current

Article History

Received: 12 November 2024

Accepted: 7 April 2025

First Online: 23 April 2025

Declarations

:

: The study was based on the guidelines for evaluating the target animal safety of new pharmaceuticals: VICH Guideline 43, and to recognized quality assurance standards (United States Food and Drug Administration (FDA) Good Laboratory Practice (GLP) Regulations, 21 Code of Federal Regulations (CFR) Part 58, and the Organisation for Economic Cooperation and Development (OECD) Series on Principles of Good Laboratory Practice). The study was reviewed and approved by both CHK’s and Elanco’s Institutional Animal Care and Use Committee. This manuscript was prepared in compliance with the ARRIVE Guidelines Checklist for animal in vivo experiments.

: Not applicable.

: These studies were funded by Elanco Animal Health. All authors are employees of Elanco Animal Health.